iotrolan has been researched along with Spinal Neoplasms in 1 studies
iotrolan: nonionic, isotonic contrast medium designed for intrathecal use; RN given refers to cpd without isomeric designation; DL-3-117 refers to stereoisomer; structure given in first source
Spinal Neoplasms: New abnormal growth of tissue in the SPINE.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Behrends, B | 1 |
| Albrecht, A | 1 |
| Bingas, B | 1 |
| Becker, H | 1 |
| Brunke, J | 1 |
| von Einsiedel, H | 1 |
| Mariss, G | 1 |
| Schmidt, K | 1 |
| Thun, F | 1 |
| Valavanis, A | 1 |
1 trial available for iotrolan and Spinal Neoplasms
| Article | Year |
|---|---|
Neural tolerance of iotrolan 300 in ascending cervical myelography: results of a multicenter study.
Topics: Adult; Aged; Cervical Vertebrae; Clinical Trials as Topic; Contrast Media; Female; Humans; Intervert | 1989 |